Time for a new tube – by PSY-23
YouTube, and their parent company Google, seem strangely quiet on the subject
A user’s guide to cannabinoid therapies in oncology
“Cannabinoid” is the collective term for a group of chemical compounds that either are derived from the Cannabis plant, are synthetic analogues, or occur endogenously. Although cannabinoids interact mostly at the level of the currently recognized cannabinoid receptors, they might have cross reactivity, such as at opioid receptors. The use of cannabinoid therapies could be effective in improving quality of life and possibly modifying malignancy by virtue of direct effects and in improving compliance or adherence with disease-modulating treatments such as chemotherapy and radiation therapy.
Focus on the Grass, Not my Ass. #NotInMyIndustry
“Predators prey, regardless of the environment.”
Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis
Canada has the highest incidence of MS worldwide. Anecdotal evidence reveals that people with MS smoke, ingest or vaporize cannabis for a multiplicity of reasons. With the legal situation in relation to use currently in flux, we undertook a study investigating patterns of use amongst people with MS and their attitudes towards the drug. There is a wide acceptance of cannabis within the MS patient community.
Manulife and Shoppers Drug Mart are teaming up to provide better access to patients
“This program will allow the patient to have a fully coordinated care approach. I think this will provide a great deal of comfort to patients and employers.”
Scientists say cannabidiol could extend pancreatic cancer patients’ lives by a matter of years
“The life expectancy for pancreatic cancer patients has barely changed in the last 40 years because there are very few, and mostly only palliative care, treatments available,”
Cannabis and epilepsy: An ancient treatment returns to the fore
Cannabis has been associated with the treatment of epilepsy throughout history, and if ancient Assyrian sources referring to “hand of ghost” are considered credible, this relationship may span four millennia. A tradition of usage continued in Arabic medicine and Ayurvedic practice in India, which led, in turn, to early experiments in Europe and North America with “Indian hemp.” Lack of standardization, bioavailability issues, and ultimately prohibition were all factors in cannabis-based medicines failing to maintain mainstream usage in seizure treatment, but investigation was resumed in the 1970s with interesting signals noted in both laboratory and clinical settings. Early case studies showed promise, but lacked sufficient rigor.
